UCSF Foundation Investment Company

UCSF's standing as the largest public recipient of NIH funding provides the investment team with direct exposure to faculty researchers, clinical trial leads, and translational science innovators. This creates proprietary insight into emerging drug development platforms, medical device technologies, and diagnostics — particularly at the early venture stage — that informs fund manager selection and, where permitted, co-investment decisions in life sciences.

The foundation endowment's specific size is not routinely broken out as a standalone figure in UC Regents public filings. The combined UC system reports total managed assets exceeding $180 billion across all pools as of mid-2023, but campus-level foundation allocations are reported in aggregated tiers that do not isolate UCSF's foundation portfolio separately.

The foundation engages across the full institutional spectrum, from early-stage venture capital to mature private equity buyouts. Its most differentiated exposure is concentrated in early-stage healthcare and life-sciences venture, where UCSF's academic network provides origination advantages. The portfolio also includes allocations to real assets, fixed income, and public equities to balance risk across the endowment timeline.